vs
Side-by-side financial comparison of ADTRAN Holdings, Inc. (ADTN) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
ADTRAN Holdings, Inc. is the larger business by last-quarter revenue ($291.6M vs $183.1M, roughly 1.6× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -1.2%, a 14.6% gap on every dollar of revenue. On growth, ADTRAN Holdings, Inc. posted the faster year-over-year revenue change (20.1% vs -1.8%). ADTRAN Holdings, Inc. produced more free cash flow last quarter ($30.6M vs $24.6M). Over the past eight quarters, ADTRAN Holdings, Inc.'s revenue compounded faster (13.5% CAGR vs 3.2%).
Adtran, Inc. is an American fiber networking and telecommunications company headquartered in Huntsville, Alabama. It is a vendor of both residential and enterprise networking equipment, along with administrative software for network management and deployment. Its customers include communications service providers, governments, enterprises and utilities.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
ADTN vs AMPH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $291.6M | $183.1M |
| Net Profit | $-3.6M | $24.4M |
| Gross Margin | 39.0% | 46.8% |
| Operating Margin | 1.5% | 19.4% |
| Net Margin | -1.2% | 13.3% |
| Revenue YoY | 20.1% | -1.8% |
| Net Profit YoY | 92.2% | -35.7% |
| EPS (diluted) | $-0.02 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $291.6M | $183.1M | ||
| Q3 25 | $279.4M | $191.8M | ||
| Q2 25 | $265.1M | $174.4M | ||
| Q1 25 | $247.7M | $170.5M | ||
| Q4 24 | $242.9M | $186.5M | ||
| Q3 24 | $227.7M | $191.2M | ||
| Q2 24 | $226.0M | $182.4M | ||
| Q1 24 | $226.2M | $171.8M |
| Q4 25 | $-3.6M | $24.4M | ||
| Q3 25 | $-10.3M | $17.4M | ||
| Q2 25 | $-20.5M | $31.0M | ||
| Q1 25 | $-11.3M | $25.3M | ||
| Q4 24 | $-46.1M | $38.0M | ||
| Q3 24 | $-33.3M | $40.4M | ||
| Q2 24 | $-49.7M | $37.9M | ||
| Q1 24 | $-330.8M | $43.2M |
| Q4 25 | 39.0% | 46.8% | ||
| Q3 25 | 38.3% | 51.4% | ||
| Q2 25 | 37.3% | 49.6% | ||
| Q1 25 | 38.4% | 50.0% | ||
| Q4 24 | 36.9% | 46.5% | ||
| Q3 24 | 36.5% | 53.3% | ||
| Q2 24 | 36.0% | 52.2% | ||
| Q1 24 | 31.1% | 52.4% |
| Q4 25 | 1.5% | 19.4% | ||
| Q3 25 | -1.0% | 13.2% | ||
| Q2 25 | -5.0% | 24.2% | ||
| Q1 25 | -1.6% | 21.9% | ||
| Q4 24 | -6.9% | 24.2% | ||
| Q3 24 | -11.5% | 29.8% | ||
| Q2 24 | -17.0% | 30.3% | ||
| Q1 24 | -153.1% | 27.9% |
| Q4 25 | -1.2% | 13.3% | ||
| Q3 25 | -3.7% | 9.0% | ||
| Q2 25 | -7.7% | 17.8% | ||
| Q1 25 | -4.5% | 14.8% | ||
| Q4 24 | -19.0% | 20.4% | ||
| Q3 24 | -14.6% | 21.1% | ||
| Q2 24 | -22.0% | 20.8% | ||
| Q1 24 | -146.2% | 25.1% |
| Q4 25 | $-0.02 | $0.51 | ||
| Q3 25 | $-0.12 | $0.37 | ||
| Q2 25 | $-0.24 | $0.64 | ||
| Q1 25 | $-0.14 | $0.51 | ||
| Q4 24 | $-0.58 | $0.74 | ||
| Q3 24 | $-0.38 | $0.78 | ||
| Q2 24 | $-0.63 | $0.73 | ||
| Q1 24 | $-4.20 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $95.7M | $282.8M |
| Total DebtLower is stronger | — | $608.7M |
| Stockholders' EquityBook value | $145.8M | $788.8M |
| Total Assets | $1.2B | $1.6B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.7M | $282.8M | ||
| Q3 25 | $93.7M | $276.2M | ||
| Q2 25 | $106.3M | $231.8M | ||
| Q1 25 | $101.3M | $236.9M | ||
| Q4 24 | $76.0M | $221.6M | ||
| Q3 24 | $88.5M | $250.5M | ||
| Q2 24 | $111.2M | $217.8M | ||
| Q1 24 | $106.8M | $289.6M |
| Q4 25 | — | $608.7M | ||
| Q3 25 | — | $608.6M | ||
| Q2 25 | — | $607.7M | ||
| Q1 25 | — | $603.9M | ||
| Q4 24 | — | $601.6M | ||
| Q3 24 | — | $596.4M | ||
| Q2 24 | — | $586.9M | ||
| Q1 24 | — | $594.0M |
| Q4 25 | $145.8M | $788.8M | ||
| Q3 25 | $141.6M | $776.7M | ||
| Q2 25 | $169.6M | $757.5M | ||
| Q1 25 | $138.9M | $751.3M | ||
| Q4 24 | $127.0M | $732.3M | ||
| Q3 24 | $205.6M | $727.7M | ||
| Q2 24 | $213.6M | $713.3M | ||
| Q1 24 | $260.8M | $672.4M |
| Q4 25 | $1.2B | $1.6B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.2B | $1.6B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $1.3B | $1.5B | ||
| Q1 24 | $1.3B | $1.6B |
| Q4 25 | — | 0.77× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.82× | ||
| Q2 24 | — | 0.82× | ||
| Q1 24 | — | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.2M | $32.9M |
| Free Cash FlowOCF − Capex | $30.6M | $24.6M |
| FCF MarginFCF / Revenue | 10.5% | 13.4% |
| Capex IntensityCapex / Revenue | 4.0% | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | $98.0M | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.2M | $32.9M | ||
| Q3 25 | $12.2M | $52.6M | ||
| Q2 25 | $32.2M | $35.6M | ||
| Q1 25 | $43.2M | $35.1M | ||
| Q4 24 | $2.4M | $29.0M | ||
| Q3 24 | $43.3M | $60.0M | ||
| Q2 24 | $19.9M | $69.1M | ||
| Q1 24 | $37.9M | $55.3M |
| Q4 25 | $30.6M | $24.6M | ||
| Q3 25 | $4.2M | $47.2M | ||
| Q2 25 | $27.5M | $25.0M | ||
| Q1 25 | $35.8M | $24.4M | ||
| Q4 24 | $-895.0K | $16.6M | ||
| Q3 24 | $37.1M | $46.2M | ||
| Q2 24 | $8.4M | $63.1M | ||
| Q1 24 | $24.4M | $46.5M |
| Q4 25 | 10.5% | 13.4% | ||
| Q3 25 | 1.5% | 24.6% | ||
| Q2 25 | 10.4% | 14.3% | ||
| Q1 25 | 14.4% | 14.3% | ||
| Q4 24 | -0.4% | 8.9% | ||
| Q3 24 | 16.3% | 24.1% | ||
| Q2 24 | 3.7% | 34.6% | ||
| Q1 24 | 10.8% | 27.1% |
| Q4 25 | 4.0% | 4.5% | ||
| Q3 25 | 2.9% | 2.8% | ||
| Q2 25 | 1.8% | 6.1% | ||
| Q1 25 | 3.0% | 6.3% | ||
| Q4 24 | 1.4% | 6.7% | ||
| Q3 24 | 2.7% | 7.2% | ||
| Q2 24 | 5.1% | 3.3% | ||
| Q1 24 | 6.0% | 5.1% |
| Q4 25 | — | 1.35× | ||
| Q3 25 | — | 3.03× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | — | 1.82× | ||
| Q1 24 | — | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADTN
| Subscriber Solutions | $96.2M | 33% |
| Optical Networking Solutions | $81.8M | 28% |
| Access Aggregation Solutions | $64.6M | 22% |
| Services And Support | $48.9M | 17% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
